Assembly Bio Expands ABI-6250 Into Liver Diseases
SOUTH SAN FRANCISCO, Calif., May 22, 2026 Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., May 22, 2026 Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its...
Foster City, California, USA – May 21, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration...
